Skip to main content

Table 3 Prognostic significance of sEV-derived ncRNAs in PDAC

From: Small extracellular vesicle non-coding RNAs in pancreatic cancer: molecular mechanisms and clinical implications

Reference

Sample

sEV Isolation

Normalization

ncRNA

Tumor type

Patients by UICC stage

Effect

UVA

MVA

I

IIA

IIB

III

IV

Mikamori et al. [127]

Plasma

EQ

cel-miR-39

miR-155

PDAC

23

High expression correlated with shorter DFS

Takahasi et al. [175]

Plasma

UC

miR-16a

miR-451a

PDAC

7

43

High expression correlated with shorter DFS/OS

Goto et al. [145]

Serum

EQ

not specified

miR-21

all PC

2

7

4

5

14

High expression correlated with shorter OS (344 days vs. 846 days)

Li et al. [53]

Plasma

EQ

RNU6, β-actin mRNA

lncSox2ot

PDAC

28

28

High expression correlated with shorter OS (12 months vs. 15 months)

Li et al. [47]

Plasma

EQ

RNU6, β-actin mRNA

circPDE8A

PDAC

47

40

High expression correlated with shorter OS (13 months vs. 16 months)

Wang et al. [84]

Serum

TEI

cel-miR-39

miR-301a-3p

all PC

20

30

High expression correlated with shorter OS

Li et al. [57]

Plasma

TEI

not specified

circIARS

PDAC

42

39

High expression correlated with shorter OS (11 months vs. 16 months)

Li et al. [49]

Plasma

EQ

not specified

miR-222

PDAC

39

34

High expression correlated with shorter OS (10 months vs. 17 months)

Kawamura et al. [161]

PVB

UC

cel-miR-39, miR-16

miRs 21, 451a, 4525

PDAC

4

27

24

High expression correlated with shorter DFS/OS

Reese et al. [155]

Serum

UC

cel-miR-39

miR-200c

PDAC

4

14

22

16

High expression correlated with shorter OS (miR-200c: 11 months vs. 18 months) (miR-200b: 9 months vs. 18 months)

miR-200b

Guo et al. [116]

Serum

EQ

β-actin

lncUCA1

all PC

20

26

High expression correlated with shorter OS

Shao et al

Serum

EQ

cel-miR-39

miR-483-3p

PDAC

18

37

6

2

High expression correlated with shorter OS

Nishiwada et al. [176]  

Plasma/Serum

TEI

miR-16

6 miR-panel (130b-5p, 133a-3p, 195-5p, 432-5p, 1229-3p, 1273f)

PDAC

3

8

14

Discovery cohort

“high risk” correlated with shorter RfS

9

12

33

26

2

Training cohort

“high risk” correlated with shorter RfS

3

22

31

1

Validation cohort I (did not receive NAT)

“high risk” correlated with shorter RfS

10

21

13

2

Validation cohort II (received NAT)

“high risk” correlated with shorter RfS

  1. cel, Caenorhabditis elegans; DFS, disease-free survival; EQ, ExoQuick (SystemBiosciences); MVA, multivariate survival analysis; n, number of patients; NAT, neoadjuvant therapy; OS, overall survival; PC, pancreatic cancer; PDAC, pancreatic ductal adenocarcinoma; PVB, portal vein blood; TEI, Total Exosome Isolation Kit (ThermoFisher); UC, ultracentrifugation; UVA, univariate survival analysis